Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.55 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.55 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.55 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13616754 | 0.91 | MAP2K1 (0.83) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL1775571 | 0.89 | MAP2K1 (0.88) | MAP2K1MAP2K2MAP2K5EIF2AK1BRAF | |
| SCHEMBL1775676 | 0.88 | MAP2K1 (1.00) | MAP2K1MAP2K2MAP2K5EIF2AK1BRAF | |
| SCHEMBL1775678 | 0.88 | MAP2K1 (1.00) | MAP2K1MAP2K2MAP2K5EIF2AK1BRAF | |
| SCHEMBL1775774 | 0.88 | MAP2K1 (1.00) | MAP2K1MAP2K2MAP2K5EIF2AK1BRAF | |
| SCHEMBL1775958 | 0.85 | MAP2K1 (1.00) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL1775479 | 0.84 | MAP2K1 (0.86) | MAP2K1MAP2K2MAP2K5EIF2AK1BRAF | |
| SCHEMBL1775478 | 0.84 | MAP2K1 (0.86) | MAP2K1MAP2K2MAP2K5EIF2AK1BRAF | |
| SCHEMBL1777781 | 0.84 | MAP2K1 (0.86) | MAP2K1MAP2K2MAP2K5EIF2AK1BRAF | |
| SCHEMBL1777900 | 0.84 | MAP2K1 (1.00) | MAP2K1MAP2K2MAP2K5EIF2AK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943659-B2 | cancerous hyperproliferative disorders; 5-Acetyl-2-(2-fluoro-4-iodo-phenylamino)-1H-pyrrole-3-carboxylic acid; 2-acetyl-5-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1-methyl-1H-imidazole-4-carboxamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | claimed |
| EP-2113500-A1 | MAPK/ERK kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2009-11-04 | — | — | EP | claimed |
| EP-2089359-A2 | MAPK/ERK KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2009-08-19 | — | — | EP | claimed |
| US-20080188453-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA CALIFORNIA, INC. | 2008-08-07 | — | — | US | claimed |
| WO-2008055236-A2 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-08 | — | — | WO | claimed |
| US-20150265679-A1 | METHOD OF REDUCING ADVERSE EFFECTS IN A CANCER PATIENT UNDREGOING TREATMENT WITH A MEK INHIBITOR | THE UNITED STATES OF AMERICA, AS REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-09-24 | — | — | US | disclosed |
| US-7943659-B2 | cancerous hyperproliferative disorders; 5-Acetyl-2-(2-fluoro-4-iodo-phenylamino)-1H-pyrrole-3-carboxylic acid; 2-acetyl-5-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1-methyl-1H-imidazole-4-carboxamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7943659-B2 | cancerous hyperproliferative disorders; 5-Acetyl-2-(2-fluoro-4-iodo-phenylamino)-1H-pyrrole-3-carboxylic acid; 2-acetyl-5-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1-methyl-1H-imidazole-4-carboxamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7943659-B2 | cancerous hyperproliferative disorders; 5-Acetyl-2-(2-fluoro-4-iodo-phenylamino)-1H-pyrrole-3-carboxylic acid; 2-acetyl-5-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1-methyl-1H-imidazole-4-carboxamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| EP-2113500-A1 | MAPK/ERK kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2009-11-04 | — | — | EP | disclosed |
| EP-2089359-A2 | MAPK/ERK KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2009-08-19 | — | — | EP | disclosed |
| US-20080188453-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA CALIFORNIA, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188453-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA CALIFORNIA, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188453-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA CALIFORNIA, INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2008055236-A2 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008055236-A2 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188453-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | MAP2K1 44/4885MAP2K2 43/4885MAP2K5 45/4885 |
| US-20150265679-A1 | METHOD OF REDUCING ADVERSE EFFECTS IN A CANCER PATIENT UNDREGOING TREATMENT WITH A MEK INHIBITOR | NRAS, BRAF, KRAS | MAP2K1 259/4885MAP2K2 209/4885MAP2K5 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.